Novo names former Galderma exec as new CFO as eight-year finance chief departs; Alnylam and Amgen also seek senior replacements

Novo's chief financial officer, who has served for eight years, will step down at the end of the year.

The company has selected an executive from Galderma to take over the CFO role, signaling a leadership transition in finance.

In other executive moves, Alnylam is searching for a new head of commercial operations after the departure of Tolga Tanguler, while Amgen is looking internally to fill its head of quality position.